Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Montanide ISA 51 + PEPIDH1M vaccine + Sargramostim + Temozolomide |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Montanide ISA 51 | ||||
PEPIDH1M vaccine | PEPIDH1M | PEPIDH1M vaccine is a peptide vaccine based on isocitrate dehydrogenase 1 (IDH1) harboring the R132H point mutation, which may induce a host immune response against tumor cells expressing IDH1 R132H (NCI Drug Dictionary). | ||
Sargramostim | Leukine | GM-CSF|Prokine | ||
Temozolomide | Temodar | Methazolastone|TMZ | Chemotherapy - Alkylating 18 | Temodar (temozolomide) is a dacarbazine analog and cytotoxic alkylating agent (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02193347 | Phase I | Montanide ISA 51 + PEPIDH1M vaccine + Sargramostim + Temozolomide | IDH1 Peptide Vaccine for Recurrent Grade II Glioma (RESIST) | Completed | USA | 0 |